Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glycopyrronium once-daily versus twice-daily in moderate to severe COPD
2014-004818-28Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Novartis. Primary endpoint: Trough Forced Expiratory Volume in 1 second (FEV1) at Week 12. Started May 2015; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2014-004818-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004818-28.